Related references
Note: Only part of the references are listed.EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104
S. Boeck et al.
BRITISH JOURNAL OF CANCER (2013)
Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer
Takeshi Ogura et al.
JOURNAL OF GASTROENTEROLOGY (2013)
Systemic treatment of advanced pancreatic cancer
Volker Heinemann et al.
CANCER TREATMENT REVIEWS (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Impact of the Specific Mutation in KRAS Codon 12 Mutated Tumors on Treatment Efficacy in Patients with Metastatic Colorectal Cancer Receiving Cetuximab-Based First-Line Therapy: A Pooled Analysis of Three Trials
Dominik P. Modest et al.
ONCOLOGY (2012)
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy
Seung Tae Kim et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Molecular Predictors of Outcome in a Phase 3 Study of Gemcitabine and Erlotinib Therapy in Patients With Advanced Pancreatic Cancer National Cancer Institute of Canada Clinical Trials Group Study PA 3
Gilda da Cunha Santos et al.
CANCER (2010)
K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer
H. Chen et al.
EJSO (2010)
Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response
Ching-Wei D. Tzeng et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplilications, and KRAS mutations on survival of pancreatic adenocarcinoma
Jeeyun Lee et al.
CANCER (2007)
An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors
ML Amador et al.
CANCER RESEARCH (2004)
Share Paper
